Genetic study on Frontotemporal Dementia in Lille

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study is part of the international GENFI2 initiative, focusing on a cohort of individuals with genetic Frontotemporal Dementia (FTD) and related disorders. It aims to enhance the understanding of symptomatic FTD patients and presymptomatic individuals at risk due to known genetic mutations. Participants will undergo a series of assessments, including clinical evaluations, neuropsychiatric tests, cognitive assessments, imaging, and biosample collection over a five-year period. The study seeks to identify biomarkers for disease progression and optimal timing for potential disease-modifying therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The participant must be 18 years old or older.
* The participant must be a member of a family with a known pathogenic mutation in the GRN or MAPT genes, or with a pathogenic expansion in the C9orf72 gene :

  * An affected member is one who has been clinically diagnosed by a neurologist as having frontotemporal dementia or a disorder in the FTD spectrum.
  * An at-risk member is one who is a first-degree relative of a family member affected with the disease.
  * Pathogenicity of a GRN or MAPT mutation is defined by those included within the GENFI list of FTD mutation. If a novel mutation is discovered that is likely to be pathogenic and has not yet been included within the FTD mutation database then the GENFI Genetics Core will decide on inclusion. Please send an email to the GENFI Trials Team at genfi@ucl.ac.uk.
  * A pathogenic C9orf72 expansion is defined as greater than 30 repeats. Intermediate expansions are not considered pathogenic.
  * Participants from one of the small number of families around the world in which 2 (or more) pathogenic mutations have been found should not be included in GENFI.
* If the participant is demented or cognitively impaired there must be an available caregiver that can escort them.
* The participant must have an identified informant.
* The participant must be fluent in the language of their country of assessment.
* The participant accepts that genetic analysis will be carried out on his/her blood samples, and that no results will be available neither for the investigator nor for the participant.

Exclusion Criteria:

* Participant has another medical or psychiatric illness that would interfere in completing assessments.
* Contraindications to FDG-PET (allergy to FDG…)
* Participant is pregnant.

Where it's running

• Hôpital Roger Salengro, CHRU de Lille - CMRR
  Lille, France Recruiting

Study contacts

• Principal investigator: Thibaud LEBOUVIER, MD, Ph — CHU de Lille
• Study coordinator: Thibaud LEBOUVIER, MD, Ph
• Email: thibaud.lebouvier@chru-lille.fr
• Phone: 03 20 44 60 21

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

• ARO-MAPT-SC in healthy adults and people with early Alzheimer's disease

  This trial will test whether ARO-MAPT-SC is safe, tolerable, and produces the expected drug levels and biomarker effects in healthy adults and people with early Alzheimer's disease.

  Recruiting at 4 sites Phase 1/2 Arrowhead Pharmaceuticals · East York, Ontario and 3 other locations · NCT07221344

• STELLA-FTD: Telehealth support program for family caregivers of frontotemporal degeneration

  This program will see if eight weekly live video group sessions help family caregivers of people with frontotemporal degeneration manage challenging behaviors and connect with community and peer resources.

  Recruiting Oregon Health and Science University · Portland, Oregon · NCT06613204

• Using vortioxetine to improve mood and cognition in patients with frontotemporal dementia

  This study is testing if a medication called vortioxetine can help improve mood and thinking skills in people with early-stage behavioral variant Frontotemporal Dementia.

  Recruiting Phase 2 Johns Hopkins University · Baltimore, Maryland · NCT06604520

• Predicting disease progression in dementia using biomarkers and modeling

  This study is trying to create a tool that helps predict how dementia will progress in people with mild cognitive impairment and different types of dementia, like Alzheimer's and Lewy Body Disease, by looking at brain scans, body fluids, and mental tests.

  Recruiting University Health Network, Toronto · North York, Ontario and 3 other locations · NCT06529744

• Comparing protein patterns in skin biopsies of neurodegenerative diseases

  This study is trying to see if the patterns of certain proteins in skin samples can help doctors better understand and diagnose different neurodegenerative diseases like Alzheimer's, Parkinson's, and frontotemporal dementia.

  Recruiting Universidad Autonoma de San Luis Potosí · San Luis Potosí City · NCT06528964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.